생명과학회지 (Journal of Life Science)

  • 제16권6호
  • /
  • Pages.1066-1070
  • /
  • 2006
  • /
  • 1225-9918(pISSN)
  • /
  • 2287-3406(eISSN)
한국생명과학회 (Korean Society of Life Science)
권호 표지
DOI QR코드

DOI QR Code

Smooth muscle cell 증식에 있어 NF-κ ligand의 receptor activator의 역할

The Role of Receptor Activator of NF-κ Ligand in Smooth Muscle Cell Proliferation

  • 김현주 (포항공과대학교 생명과학부)
  • Kim, Hyun-Ju (Division of Molecular and Life Sciences, Pohang University of Science and Technology)
  • 발행 : 2006.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Smooth muscle cell (SMC)의 증식은 혈관성장에 의한 질환의 발병기전의 중요한 요소이다. 혈관 손상 후 SMC의 성장조절에 대한 분자적 기작에 대한 연구는 치료제 개발에 있어 중요한 의미를 지닌다. 이에, 본 연구에서는 TNF family인 RANKL가 SMC의 증식을 촉진함을 입증하였다. RANKL는 p21의 발현을 감소시키고 p21의 promoter활성을 저해함으로써 SMC의 성장을 증가시켰다. 또한 ERK와 p38 MAPK의 활성이 RANKL에 의해 증가하였으며, ERK/p38의 저해제는 RANKL에 의해 유도되는 SMC의 성장을 완전히 억제하였다. 이러한 결과는 ERK와 p38 MAPK가 RANKL에 의해 유도되는 SMC의 증식에 중요한 역할을 함을 보여주는 것이다. 즉, RANK-RANKL-ERK/p38이 SMC의 증식을 매개하는 중요 분자이며, 이들 분자는 혈관 질환을 막는 새로운 치료제 개발의 표적분자가 될 수 있음이 입증되었다.

Smooth muscle cell (SMC) proliferation is important in the pathogenesis of vascular proliferative disorders. Understanding of the molecular mechanism underlying SMC growth after arterial injury would have therapeutic implications. Here we report that receptor activator of $NF-{\kappa}B$ ligand (RANKL), a member of tumor necrosis factor (TNF) family, promotes the proliferation of SMC, leading to decreased expression of p21 and enhancement of SMC growth. ERK and p38 phosphorylation was enhanced after RANKL treatment in SMC. Inhibition of ERK/p38 MAPK activity by PD98059/SB203580 completely abolished RANKL-induced proliferation of SMC, indicating ERK and p38 MAPK are essential for RANKL-induced SMC proliferation. Taken together, our findings demonstrate that RANK-RANKL-ERK/p38 pathway is important for proliferation of SMC and that these molecules may be the new therapeutic targets for the prevention of vascular diseases.

키워드

참고문헌

  1. Cano, E. and L. C. Mahadevan 1995. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20, 117-122 https://doi.org/10.1016/S0968-0004(00)88978-1
  2. Fata, J. E., Y. Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R. A. Moorehead, R. Elliott, S. Scully, E. B. Voura, D. L. Lacey, W. J. Boyle, R. Khokha and J. M. Penninger. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 https://doi.org/10.1016/S0092-8674(00)00103-3
  3. Force, T. and J. V. Bonventre 1998. Growth factors and mitogen- activated protein kinases. Hypertension 31, 152-161 https://doi.org/10.1161/01.HYP.31.1.152
  4. Hayashi, K., M. Takahashi, K. Kimura, W. Nishida, H. Saga and K. Sobue.1999. Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen- activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells. J. Cell Biol. 145, 727-740 https://doi.org/10.1083/jcb.145.4.727
  5. Izumi, Y., S. Kim, M. Namba, H. Yasumoto, H. Miyazaki, M. Hoshiga, Y. Kaneda, R. Morishita, Y. Zhan and H. Iwao. 2001. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon- injured rat artery. Cir. Res. 88, 1120-1126 https://doi.org/10.1161/hh1101.091267
  6. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, C. Capparelli, A. Eli, Y. X. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, J. Guo, J. Delaney and W. J. Boyle.1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 https://doi.org/10.1016/S0092-8674(00)81569-X
  7. Larrivee, J. F., D. R. Bachvarov, F. Houle, J. Landry, J. Huot and F. Marceau. 1998. Role of the mitogen-activated protein kinases in the expression of the kinin B1 receptors induced by tissue injury. J. Immunol. 160, 1419-1426
  8. Lee, W. S., J. A. Harder, M, Yoshizumi, M.E. Lee and E. Haber.1997. Progesterone inhibits arterial smooth muscle cell proliferation. Nat. Med. 3, 1005-1008 https://doi.org/10.1038/nm0997-1005
  9. Libby, P., D. Schwartz, E. Brogi, H. Tanaka and S. K. Clinton. 1992. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86, 11147-11152
  10. Matsumura, M. E., D. R. Lobe and C. A. McNamara. 2002. Contribution of the helix-loop-helix factor Id2 to regulation of vascular smooth muscle cell proliferation. J. Biol. Chem. 277, 7293-7297 https://doi.org/10.1074/jbc.M108986200
  11. Mueller, C., S. Baudler, H. Welzel, M. Bohm and G. Nickenig. 2002. Identification of a novel redox-sensitive gene, Id3, which mediates angiotensin II-induced cell growth. Circulation 105, 2423-2428 https://doi.org/10.1161/01.CIR.0000016047.19488.91
  12. Prabhu, S., A. Ignatova, S. T. Park and X. H. Sun.1997. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol. Cell Biol. 17, 5888-5896 https://doi.org/10.1128/MCB.17.10.5888
  13. Pyles, J. M., K. L. March, M. Franklin, K. Mehdi, R. L. Wilensky and L. P.Adam. 1997. Activation of MAP kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries. Cir. Res. 81, 904-910 https://doi.org/10.1161/01.RES.81.6.904
  14. Raines, E. W., S. K. Dower and R. Ross. 1989. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 243, 393-396 https://doi.org/10.1126/science.2783498
  15. Reidy, M. A., J. Fingerle and V. Linder,. 1992. Factors controlling the development of arterial lesions after injury. Circulation 86, 11143-11146
  16. Schwartz, S. M. 1999. The intima : A new soil. Cir Res. 82(10), 877-879
  17. Stouffer, G. A. and G. K. Owens. 1994. TGF-beta promotes proliferation of cultured SMC via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J. Clin. Invest. 86, 2048-2055
  18. Warner, S. J., G. B. Friedman and P. Libby. 1989. Immune interferon inhibits proliferation and induces 2'-5'-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J. Clin. Invest. 83, 1174-1182 https://doi.org/10.1172/JCI113998
  19. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080 https://doi.org/10.1084/jem.186.12.2075
  20. Wong, B. R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. S. Bartlett, W. N. Frankel, S. Y. Lee and Y. Choi. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Bio. Chem. 272, 25190-25194 https://doi.org/10.1074/jbc.272.40.25190